Biotech Industry, Biotech News, Biotechnology Articles, exl pharma.#Exl #pharma


Posted On Feb 28 2018 by

exl pharma

Certain microRNAs in the saliva of concussion patients could help gauge the severity of concussions and predict the length of concussion symptoms.

Exl pharma

Toxicity knocks Ardelyx s hyperkalemia hopes back to preclinic

Unexpected side effects have spelled the end for Ardelyx’s drug candidate to treat elevated potassium levels in the blood, which was in phase 3 testing.

Exl pharma

Cytokinetics cans lead drug after phase 3 ALS wipeout

Cytokinetics canned tirasemtiv after it failed to beat placebo against the primary endpoint or any of the secondary goals in an ALS trial.

Exl pharma

Step Pharma bags cash for CTPS1 autoimmune R D drive

The $17 million financing equips the lean French biotech to prepare its CTPS1 inhibitors for clinical testing in autoimmune disorders.

Exl pharma

PTK6 blocker could treat or even prevent ER+ breast cancer metastasis

The enzyme PTK6 could be targeted to quell the growth of estrogen receptor-positive breast cancer, a common form of the disease.

Exl pharma

Amsterdam beats out Milan to host EMA

After tying with Milan in a third round of voting, Amsterdam will be the new home of the European Medicines Agency.

Exl pharma

LivaNova to offload Cardiac Rhythm unit for $190M

LivaNova will sell its Cardiac Rhythm Management business to its joint venture partner, MicroPort Scientific.

Exl pharma

DBV climbs as peanut allergy safety data come in clean

Shares in DBV rose on the back of the data, going a little way to erasing the big drop it suffered after missing its primary efficacy endpoint.

Exl pharma


Last Updated on: February 28th, 2018 at 7:47 pm, by


Written by admin


Leave a Reply

Your email address will not be published. Required fields are marked *